US 11,919,912 B2
Modulators of methyl modifying enzymes, compositions and uses thereof
Alexandre Côté, Cambridge, MA (US); Avinash Khanna, Cambridge, MA (US); and Ludivine Moine, Cambridge, MA (US)
Assigned to Constellation Pharmaceuticals, Inc., Boston, MA (US)
Appl. No. 17/057,225
Filed by Constellation Pharmaceuticals, Inc., Boston, MA (US)
PCT Filed May 17, 2019, PCT No. PCT/US2019/032926
§ 371(c)(1), (2) Date Nov. 20, 2020,
PCT Pub. No. WO2019/226491, PCT Pub. Date Nov. 28, 2019.
Claims priority of provisional application 62/674,141, filed on May 21, 2018.
Prior Publication US 2021/0206776 A1, Jul. 8, 2021
Int. Cl. C07D 491/056 (2006.01); A61K 31/435 (2006.01); A61P 35/00 (2006.01)
CPC C07D 491/056 (2013.01) [A61P 35/00 (2018.01)] 18 Claims
 
1. A compound of the Formula:

OG Complex Work Unit Chemistry
or a pharmaceutically acceptable salt thereof, wherein
R1 is halo, (C1-C4)alkyl, halo(C1-C4)alkyl, —O(C1-C4)alkyl, or —O[halo(C1-C4)alkyl], —S(C1-C4)alkyl, or —S[halo(C1-C4)alkyl];
R2 is hydrogen, halo, or (C1-C4)alkyl;
R3 is (C1-C4)alkyl or halo(C1-C4)alkyl;
R4 is halo, (C1-C4)alkyl, or halo(C1-C4)alkyl;
R5 is hydrogen, (C1-C4)alkyl, or halo(C1-C4)alkyl;
R6 is halo, (C1-C4)alkyl, or halo(C1-C4)alkyl; or
R5 and R6 together with the nitrogen atom to which they are attached form a 4-to 7-membered heterocyclyl optionally substituted with 1 to 3 groups selected from halo, (C1-C4)alkyl, halo(C1-C4)alkyl, and —OW;
R7 is (C1-C4)alkyl, halo(C1-C4)alkyl, or (C3-C7)cycloalkyl; and
the dashed line represents a single or double bond.